<DOC>
	<DOCNO>NCT02554812</DOCNO>
	<brief_summary>This Phase 1b/2 dose-optimization study evaluate safety , pharmacokinetics , pharmacodynamics , preliminary antitumor activity avelumab ( MSB0010718C ) combination cancer immunotherapies patient locally advance metastatic solid tumor . The primary purpose ass safety early sign efficacy various avelumab combination cancer immunotherapy , optimize dose regimen appropriate , limited series indication .</brief_summary>
	<brief_title>A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies ( JAVELIN Medley )</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Histological cytological diagnosis advanced/metastatic solid tumor . Combination A : Phase 1b , patient NSCLC progress standard therapy standard therapy available , Phase 2 , patient NSCLC , melanoma , SCCHN , TNBC line therapy , SCLC , 1st line NSCLC . Combination B : Phase 1b , patient advance solid tumor progress standard therapy standard therapy available , Phase 2 , patient NSCLC , melanoma , SCCHN line therapy , locally advanced/metastatic CRC progress 1 line standard therapy . NSCLC patient Phase 2 tumor ALK EGFR mutation must receive refractory/intolerant standard therapy . Combination C : Ovarian cancer , SCCHN , NSCLC , gastric cancer , progress least 1 line standard therapy ineligible for/intolerant SOC . Combination D : NSCLC , melanoma , SCCHN progress least 1 line standard therapy ineligible for/intolerant SOC . ECOG performance status 0 1 Estimated life expectancy least 3 month Adequate bone marrow , renal , liver function Resolved acute effect prior therapy Negative serum pregnancy test screen Male female patient able child must agree use 2 highly effective method contraception throughout study least 60 day last dose Signed date informed consent Monoclonal antibody base anticancer therapy within 28 day prior study entry smallmolecule base anticancer therapy ( targeted therapy chemotherapy ) within 14 day prior study entry . Current prior use immunosuppressive medication within 7 day prior study entry Active autoimmune disease require systemic steroid immunosuppressive agent within 7 day prior study entry Known prior suspect hypersensitivity investigational product Major surgery within 4 week radiation therapy within 14 day prior study entry Patients know symptomatic brain metastasis require steroid Previous highdose chemotherapy require stem cell rescue Prior allogeneic stem cell transplant organ graft Any follow within 6 month prior study entry : myocardial infarction , uncontrolled angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack Symptomatic pulmonary embolism within 6 month prior study entry Known HIV AIDSrelated illness Active infection require systemic therapy Positive HBV HCV test indicate acute chronic infection Administration live vaccine within 4 week prior study entry Diagnosis malignancy within 5 year , except adequately treat basal cell squamous cell skin cancer , carcinoma situ breast cervix , lowgrade ( Gleason â‰¤6 ) prostate cancer Participation study involve investigational drug ( ) within 4 week prior study entry and/or study participation Persisting toxicity relate prior therapy &gt; Grade 1 Other severe acute chronic medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>anti PD-L1</keyword>
	<keyword>anti 4-1BB</keyword>
	<keyword>Non-small cell lung cancer ( NSCLC )</keyword>
	<keyword>melanoma</keyword>
	<keyword>squamous cell carcinoma head neck ( SCCHN )</keyword>
	<keyword>triple negative breast cancer ( TNBC )</keyword>
	<keyword>colorectal cancer ( CRC )</keyword>
</DOC>